# A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

> **NCT01057667** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 168 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** RO5024048
- **DRUG:** Ribavirin [Copegus]
- **DRUG:** peginterferon alfa-2a [Pegasys]

## Key facts

- **NCT ID:** NCT01057667
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01057667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01057667, "A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01057667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*